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a b s t r a c t
Efforts to cure HIV-1 infections aim at eliminating proviral DNA. Integrated DNA from various viruses
often becomes methylated de novo and transcriptionally inactivated. We therefore investigated CpG
methylation proﬁles of 55 of 94 CpG's (58.5%) in HIV-1 proviral genomes including ten CpG's in each LTR
and additional CpG's in portions of gag, env, nef, rev, and tat genes. We analyzed 33 DNA samples from
PBMC's of 23 subjects representing a broad spectrum of HIV-1 disease. In 22 of 23 HIV-1-infected
individuals, there were only unmethylated CpG's regardless of infection status. In one long term
nonprogressor, however, methylation of proviral DNA varied between 0 and 75% over an 11-year period
although the CD4þ counts remained stable. Hence levels of proviral DNA methylation can ﬂuctuate.
The preponderance of unmethylated CpG's suggests that proviral methylation is not a major factor in
regulating HIV-1 proviral activity in PBMC's. Unmethylated CpG's may play a role in HIV-1 immuno-
pathogenesis.
& 2013 Elsevier Inc.
Introduction
Treatment with highly active antiretroviral therapy (HAART)
has not only led to suppression of plasma viremia in many patients
but also to a dramatic reduction in the rates of illness and death in
HIV-1-infected individuals (Anastos et al., 2004; Ledergerber et al.,
1999). HIV-1 cure, however, has not been attained despite HAART
due to the persistence of proviral DNA integrated into the host
genome (Persaud et al., 2000; Trono et al., 2010). Strategies to cure
HIV-1 need to aim at modifying or eliminating proviral DNA from
the cellular genomes. Recent work, however, has revealed that
individuals chronically infected with HIV-1 harbor a reservoir of
integrated proviral DNA many times larger than previously esti-
mated (Ho et al., 2013). Elimination of these proviruses presents a
major challenge, making the characterization of integrated pro-
viruses across the genome a high priority.
To better understand the state of proviral DNA in infected
individuals, we characterized epigenetic modiﬁcations including
uniquely located CpG methylation in a number of HIV-1 proviral
DNA genes obtained from HIV-1-infected individuals; these sub-
jects represented a spectrum of HIV-1 disease progression. Latent
HIV-1 proviruses are thought to reside in a proportion of resting
CD4þ cells (Persaud et al., 2000; Trono et al., 2010). As a ﬁrst step
in analyzing methylation patterns, we chose to limit our approach
to the analysis of methylation patterns in integrated HIV-1 proviral
DNA from PBMC's. The selection of cells in culture requires the
application of methods that might fundamentally alter the actual
proﬁles of proviral CpG methylation.
Foreign DNA integrated into mammalian genomes can become
methylated de novo, as was recognized early on for the genomes of
DNA viruses (Desrosiers et al., 1979; Hochstein et al., 2007; Kalantari
et al., 2008; Sutter et al., 1978; Sutter and Doerﬂer, 1980; Takacs
et al., 2010) and retroviruses (Christman et al., 1980; Hoffmann et al.,
1982; Stuhlmann et al., 1981). Speciﬁc viral genome segments can
be permanently silenced in this way. HIV-1 proviral genomes in
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human cells have also been studied for their patterns of DNA
methylation to gain insight into the mechanisms underlying the
long-term fate of HIV-1 infections. Methylation studies of HIV-1
initially analyzed infected cells in cell culture and demonstrated that
methylation of CpG residues in vitro can lead to the transcriptional
inactivation of HIV-1 LTR's. These results suggested that methylation
might play a role in HIV-1 latency (Bednarik et al., 1987, 1990;
Blazkova et al., 2009; Chavez et al., 2011; Fang et al., 2001;
Gutekunst et al., 1993; Ishida et al., 2006; Jeeninga et al., 2008;
Kauder et al., 2009; Mok and Lever, 2007; Pion et al., 2003; Schulze-
Forster et al., 1990; Tanaka et al., 2003; Terme et al., 2009). Proviral
HIV-1 genomes can be reactivated by treating cultured cells with
5-azacytidine, a well-known inhibitor of DNA methyltransferase
systems (Tanaka et al., 2003). Modiﬁcations of the histone code in
the HIV-1 LTR regions can also be involved in establishing HIV-1
latency (Duverger et al., 2009; Friedman et al., 2011; Suzuki et al.,
2005; Van Duyne et al., 2008). The complex problem of latency with
multifactorial causation, however, continues to pose a major chal-
lenge for HIV-1 cure in infected individuals (Cohen, 2011).
Studies on DNA methylation in HIV-1 genomes from infected
individuals are far fewer, and the patient populations and pub-
lished results differ. In PBMC's taken directly from HIV-1-infected
patients, one report has found 20% to 100% methylated CpG's in
proviral DNA (Blazkova et al., 2009). A later study has described
that the HIV-1 5′LTR's are scarcely methylated in latently infected,
resting CD4(þ) T cells from aviremic HIV-1 infected individuals on
HAART (Blazkova et al., 2012). By contrast, Palacios et al. (2012)
report that in long term nonprogressors (LTNP's) and elite con-
trollers, there might be a low level of methylation, whereas in
patients with suppressed viremia due to HAART, methylation is
virtually absent. These previous studies of HIV-1 obtained from
infected subjects focused mainly on the 5′LTRs of the proviral
genomes. In PBMCs, monocytes, and CD4þ T cells from feline
immune deﬁciency virus (FIV)-infected cats, no evidence has been
obtained for hypermethylation in the 5′- and 3′-LTR's of the FIV
proviral genomes (Murphy et al., 2012).
The present investigation extends previous studies of HIV-1
methylation in infected individuals in several ways. We examined
a large group of patients with a broad spectrum of HIV-1 disease
progression and serial samples obtained over a period of years.
Furthermore, we analyzed the integration status of HIV-1 DNA and
the methylation patterns in several genes encompassing 55 of the
94 CpG (58.5%) dinucleotides in the total HIV-1 proviral genome, a
signiﬁcantly larger portion of the viral genome than studied previously.
Results
Study population
We studied 23 individuals (10 women and 13 men) with a
broad range of HIV-1 infection. Six individuals were documented
to be elite controllers (Okulicz et al., 2009), 4 were LTNP's (Okulicz
et al., 2009), and 13 had progressive disease (Table 1). Subjects
with identiﬁcation codes starting with "W" were participants in
the Bronx, NY site of the Women's Interagency HIV Study (WIHS),
a natural history investigation of HIV-1 infection in women
(Anastos et al., 2004). Subjects whose codes start with "T" were
members of the Maple Leaf Clinic Cohort in Toronto, Canada, and
those with code numbers starting with "9" or “13”were from the
Department of Virology, Erlangen University Medical School.
Proviral genome segments investigated
The HXB2-K03455 sequence (http://www.ncbi.nlm.nih.gov)
used as the reference for HIV-1 proviral DNA throughout this
study contains a total of 94 CpG's. The map in Fig. 1A describes the
distribution of the CpG's in the 5′ and 3′ regions of the HIV-1
proviral genomes. The locations of the HIV-1 genes are also
indicated. Of a total of 94 CpG dinucleotides in the HIV genome,
we screened 55 for their methylation status. Thirty-one CpG's in
the 5′ region were studied; these were numbered 2 to 32 and
included 10 of 11 CpG's in the 5′-LTR and 21 CpG's in the gag gene.
In the 3′-region, we analyzed 24 CpG's, 10 of 11 in the 3′-LTR, and
15 CpG's representing portions of the nef, rev, tat, and env (gp41)
genes. The CpG very close to the terminus of either LTR could not
be analyzed due to insufﬁcient sequence lengths for primer
binding.
Intracellular forms of HIV-1 DNA in PBMC's
Two sets of primers were selected to characterize the intracel-
lular forms of HIV-1 genomes in PBMC's. To access the integrated
HIV-1 genomes, one primer was placed inside the LTR, the other
one in adjacent cellular AluI sequences. The possible occurrence of
2-LTR HIV circles (Graf et al., 2011; Sloan and Wainberg, 2011) was
assessed by using a PCR primer pair placed inside either LTR
sequence. Except for the DNA sample from one elite controller
(TR15), which contained small amounts of 2-LTR circles, the HIV-1
DNA sequences of the HIV-1 infected individuals analyzed here
were exclusively in the integrated proviral form (Table 2). The data
thus conﬁrmed the integrated state of almost all HIV-1 proviral
genomes in the DNA samples analyzed in this study. Circular 2-LTR
HIV-1 DNA was not found in most samples, although the recon-
struction experiments described under Methods documented that
the procedure employed for DNA extraction permitted the ready
isolation and subsequent detection of small circular DNA of about
5.6 kbp or of 14.8 kbp, a size range within that of the 9.7 kbp of 2-
LTR circles.
Methylation proﬁles of HIV-1 genomes in PBMC's from infected
individuals
By using the bisulﬁte sequencing technique (Frommer et al.,
1992; Clark et al., 1994), we determined methylation proﬁles in
PBMC-derived proviral DNA from HIV-1-infected individuals
(Table 1). The following HIV-1 proviral genome segments were
targeted by appropriate primer selection: 10 of 11 CpGs in the 5′-
LTR, portions of the gag, env, and auxiliary genes nef, rev, tat, as
well as 10 of 11 CpGs in the 3′-LTR (Fig. 1B and C, map in Fig. 1A).
The number of bisulﬁte-sequenced clones analyzed in different
DNA samples ranged from 2 to 84. Out of 88 samples tested, we
were able to amplify the selected regions of the HIV-1 genome in
33 DNA samples (37.5%) that were derived from 23 HIV-1 infected
individuals (Table 3).
An exemplary selection of the results is shown in Fig. 1B–F. The
CpG's analyzed from chronically infected patient 901271 (Fig. 1B)
were unmethylated in the 5′ and 3′-regions, as graphically
depicted by open squares representing unmethylated CpG's. For
chronically infected subject 901251 (Fig. 1C), the proportion of
unmethylated CpG's was again close to 100% in all regions
investigated in the proviral genome. In individual TR19 03/97, a
long term nonprogressor (Fig. 1D), close to 100% of the CpG's in the
regions analyzed were unmethylated as well. Similarly in indivi-
dual W-350 05/2002, an elite controller, all CpG's were unmethy-
lated in all regions studied in the proviral genome (Fig. 1E). In
these four methylation proﬁles, both the 5′- and 3′-LTR were
included in the analyses and found to be unmethylated. Because
the 5′-terminal region of HIV-1 proviral genomes carries function-
ally important signals, we determined the methylation proﬁles
in this HIV-1 genome segment in an additional 3 DNA samples
from 3 HIV-1 infected individuals (Table 1). Again, the CpG's in the
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5′-terminal segments were unmethylated in all samples analyzed
(Fig. 1F). Similar results were obtained for an additional 22 DNA
samples from 15 patients (Tables 1 and 3). This ﬁnding under-
scores the lack of CpG methylation in the majority of HIV-1
infected individuals studied. The few seemingly methylated CpG's
(black squares in Fig. 1B–E) were due to rare incomplete conver-
sions of cytosine residues during the bisulﬁte reaction, because
repeated analyses of the same region did not reveal methylation of
the same CpG's. It is important to emphasize that regardless of
infection outcome, whether subjects under study were chronically
infected, LTNP's or elite controllers; both 5′- and 3′-LTR's plus the
additional viral genome segments analyzed proved completely
unmethylated.
The bisulﬁte analyses of proviral DNA from subject W-1, an
LTNP who had been HIV-1 infected for 48 years when her ﬁrst
PBMC sample was obtained (Tables 1 and 3), revealed a much
more complex situation. HIV-1 genomes from this person were
studied longitudinally over an eleven-year period, and the pat-
terns of methylation differed markedly with time (Table 3, lines 1–
4; Fig. 2). In 06/1995, the CpG's investigated in the 3′ region of the
proviral DNA were all unmethylated (Fig. 2A; Table 3, line 1). At
later times, however, variable patterns of CpG methylation were
detected. In 05/1996, there were 65% methylated CpG's in the 5′
region and 72% methylated CpG's in the 3′region (Fig. 2B; Table 3,
line 2). Seven years later, 04/2003, 32% methylated CpG's were
observed in the 3′region (Fig. 2C; Table 3, line 3). Finally, in 04/
2006, the CpG's in the 3′region of individual W-1 were again
found unmethylated (Fig. 2D; Table 3, line 4). A forensic analysis of
the specimens analyzed conﬁrmed that all DNA samples tested in
this series were derived from individual W-1. Thus a longitudinal
survey of proviral methylation proﬁles encompassing a period of
11 years revealed considerable ﬂuctuations in the presence of this
epigenetic (defense) signal. The CD4þ counts of LTNP individual
W-1 were examined over the same time period. We did not ﬁnd
a signiﬁcant difference among the CD4þ counts, including the
04/2006 time point (Table 1). Dichotomizing the values before and
after this time point also did not yield any signiﬁcant differences.
In addition, the subject was clinically well and did not receive
antiretroviral therapy during the entire period. These ﬁndings
indicated that the HIV-1 infection of individual W-1 had remained
stable between 1995 and 2006.
No 5-hydroxymethylcytosine (5-hmC) in the HIV-1 proviral DNA
analyzed
In the demethylation pathway of DNA, which converts 5-mC to
unmodiﬁed C residues, 5-hmC is generated as the ﬁrst product (Jin
et al., 2010; Krais et al., 2011; Kriaucionis and Heintz, 2009;
Tahiliani et al., 2009). Because bisulﬁte sequencing does not
permit the discrimination between 5-mC and 5-hmC, we analyzed
the DNA samples with a high degree of CpG methylation (Fig. 2B
and C; Table 3) for the presence of 5-hmC. An immunological
colorimetric quantiﬁcation assay (Methods section) was used. This
technique did not facilitate interrogation of individual CpG dinu-
cleotides, but yielded cumulative results over a region. The data
indicated that the DNA from sample W-1 05/1996 (Fig. 2B; Table 3)
contained o0.1% of 5-hmC. In two additional samples W-1 04/
2003 and W-1 04/2006, no evidence for the presence of 5-hmC
was obtained. We conclude that 5-hmC is not a signiﬁcant C
Table 1
Characteristics of HIV-1-infected individuals whose PBMC derived proviral genomes were analyzed. AA, African American; H, Hispanic; C, Caucasian, NA, information not
available.
Subject Sex Ethnicity Date Plasma HIV-1 RNA Load (copies/ml) CD4 Count (cells/mm3) ART Clinical status
W-1 F AA 06/1995 464 ND None LTNP
05/1996 431 800 None LTNP
04/2003 280 1074 None LTNP
04/2006 250 623 None LTNP
W-21 F AA 01/1997 240 1849 None LTNP
03/2001 530 1774 None LTNP
06/2006 2,000 1278 None LTNP
W-360 F C 07/1996 21,130 972 None LTNP
TR19 M C 03/1997 5579 560 None LTNP
W-20 F H 09/1997 o48 1174 None Elite Controller
04/2006 o80 1826 None Elite Controller
07/2006 230 1143 None Elite Controller
W-350 F AA 05/2002 o80 917 None Elite Controller
10/2002 o80 784 None Elite Controller
W-351 F AA 03/2002 110 886 None Elite Controller
W-352 F AA 03/2002 o80 ND None Elite Controller
01/2006 o80 601 None Elite Controller
07/2006 o80 1032 None Elite Controller
TR15 M C 03/2007 o50 650 None Elite Controller
TR16 M C 12/2006 110 610 None Elite Controller
W-4 F AA 08/1999 110,000 135 None AIDS
W-17 F H 06/1999 480,000 0 D4T,EFV, NVF AIDS
901148 M NA 02/2009 12,000 NA None Chronic infection
901196 M C 02/2009 38,000 NA None Chronic infection
901251 F NA 02/2009 63,000 NA None Chronic infection
901271 M C 02/2009 130,000 NA None Chronic infection
901330 M C 02/2009 470,000 NA None Chronic infection
901448 M C 02/2009 36,000 NA None Chronic infection
901496 M NA 02/2009 670,000 NA None Chronic infection
901498 M NA 02/2009 180,000 NA None Chronic infection
135945 M C 05/2013 1400,000 NA None Chronic infection
138399 M C 07/2013 37,000 NA None Chronic infection
139847 M C 08/2013 32,000 NA None Chronic infection
F¼female, M¼male; AA¼African American; H¼Hispanic; C¼Caucasian;
NA¼ information not available; D4T¼Stavudine; EFV¼Efavirenz, NVF¼Nelﬁnavir.
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Fig. 1. DNA methylation proﬁles in the HIV-1 proviruses in PBMC’s from seven HIV-1 infected individuals. (A) This map of the HIV-1 genome is based on the HXB2-K03455
reference sequence (http://www.ncbi.nlm.nih.gov) and locates important viral genes and 32 CpG’s in 922 bp in the 5′-region as well as 24 CpG’s in 1124 bp in the 3′- region
of the HIV-1 proviral genome. The 31 CpG’s in the 5′-region and the 24 CpG’s in the 3′- region were interrogated for their methylation status. In the 5′ and 3′ LTR’s, 10 of 11
CpG’s were analyzed for methylation. One CpG immediately close to the terminus of the HIV-1 genome in either LTR could not be accessed because of limitations in primer
binding at the termini. Twenty-one CpG’s in the 5′-region fall within the CpG-rich part of the gag segment. In addition to the 10 CpG’s in the 3′ LTR, 14 CpG’s in the viral env,
tat, rev, and nef genes were analyzed. (B) Methylation proﬁles of the HIV-1 proviral DNA from PBMC’s of chronically infected patient 901271. (C) Methylation proﬁles of the
HIV-1 proviral DNA from PBMC’s of chronically infected patient 901251. (D) Methylation proﬁles of the HIV-1 proviral DNA from PBMC’s of long-term non-progressor (LTNP)
TR19 03/1997. (E) Methylation proﬁles of the HIV-1 proviral DNA from PBMC’s of elite controller W-350 05/2002. (F) DNA methylation patterns exclusively in the 5′-region of
HIV-1 proviruses in PBMC’s from an additional three HIV-1 infected individuals, 135945, 138399, and 139847. Each square denotes either unmethylated □ or methylated ■
CpG’s. Each row of squares depicts the data from one proviral molecule, each column the data of one CpG position in the proviral DNA. Detailed information on the HIV-1
infected individuals was summarized in Table1.
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modiﬁcation in HIV-1 proviral genomes in the few samples in
which 5-mC had been found.
Discussion
DNA methylation has been recognized as one of the ﬁrst
epigenetic signals with an essential function in long-term gene
regulation in eukaryotic biology including genomically integrated
viral genomes (for reviews, Doerﬂer, 1983, 2011). By intent and
experimental design, we chose to study CpG methylation proﬁles
in HIV-1 proviral genomes in human PBMC's and, for the time
being, avoided to bias the results by the use of cell selection or of
cell culture systems.
New ﬁndings
The present study breaks new ground and differs in a number of
signiﬁcant aspects from those communicated previously (Blazkova
et al., 2009, 2012; Palacios et al., 2012). We investigated the
methylation proﬁles of proviral DNA in 23 HIV-1 infected individuals
including several studied longitudinally over time (Tables 1 and 3).
Although previous studies focused mainly on the 5′-LTR, we
extended this investigation to examine more than 58%, i.e. 55 out
of the total of 94 CpG's in the entire HIV-1 genome for their
methylation status. We included in the analysis not only the 5′ and
3′ LTR's, but also portions of the gag and env genes, and the auxiliary
genes nef, rev, and tat. Moreover, single HIV-1 proviral genomes were
analyzed by bisulﬁte sequencing, and these sequences were derived
exclusively from integrated HIV-1 DNA. We detected a small fraction
of 2-LTR circles in only one DNA sample analyzed here.
There is an underrepresentation of CpG dinucleotides in the
HIV-1 genome (Karlin et al., 1994); nevertheless there are CpG
clusters in parts of the HIV-1 genome (Fig. 1). Unmethylated CpG's
have the capability to induce a range of host immune responses
(Hartmann and Krieg, 2000; Krieg, 1996). Oligonucleotides which
contain unmethylated CpGs serve as agonists for Toll-like receptor 9
(TLR9) (Jiang et al., 2008; Malaspina et al., 2008). TLR9 polymorph-
isms have been found to play a role in HIV-1 disease progression,
illustrating the contribution of TLR9 in HIV-1 immunopathogenesis
(Pine et al., 2009). We hypothesize that the unmethylated CpG's in
the HIV-1 proviral genomes may serve as agonists for TLR9 and
thereby inﬂuence HIV-1 immunopathogenesis.
Methylation proﬁles of HIV-1 genomes in PBMC's from infected
individuals
We have now analyzed PBMC derived DNA samples from 23
HIV-1 infected individuals with a wide range of infection outcomes. In
some samples, we analyzed up to 84 single HIV-1 proviral DNA
molecules to address the possibility of variations in their epigenetic
characteristics. DNA samples from 13 patients with HIV-1 disease
progression and a range of viral loads; 6 elite controllers; and 3 of
4 LTNP's were analyzed for methylation status in 55 of a total of 94
CpG's. Regardless of clinical status, the 10 of 11 CpG’s in the 5′ and 3′-
LTR’s and 35 CpG’s in parts of the gag, env, nef, rev, and tat genes in
HIV-1 proviral DNA remained unmethylated in 22 of the 23 indivi-
duals studied here (Table 3; Fig. 1A–F). By unknown means, HIV-1
proviral genomes are capable of escaping the cellular defence
mechanism of de novo methylation. This conclusion holds for the
proviral genomes in PBMC’s examined here but cannot be extrapo-
lated to viral genomes in other cell types of HIV-1 infected individuals.
In contrast, we observed that LTNP W-1 (Table 1), who had
harbored integrated proviruses for many years without developing
AIDS, presented with a time-dependent proﬁle of proviral methy-
lation that was much more complex (Fig. 2). During 11 years of
follow-up, subject W-1 had viral loads that were consistently
o500 copies/mL, stable CD4 counts in the normal range, and an
Table 2
Search for 2-LTR HIV-1 DNA circles. PCR analyses were performed with DNA
samples from individuals as indicated. Primers were selected inside the two LTR’s.
In samples W-1, W-21, W-20, W-350, and W-351, two or three time points after
HIV-1 infection were screened. To document the presence of proviral genomes, one
primer was placed inside the LTR, the second one in a cellular Alu I sequence. In all
instances, signals characteristic for proviral genomes were detected. The successful
extraction of small circular DNA in the size range between 5.65 and 14.8 kbp i.e.
that of 2-LTR circles, was veriﬁed by the control experiment described under
Methods.
Long term nonprogressors 2-LTR circles Proviral DNA
W-1 Negative Positive
W-21 Negative Positive
W-360 Negative Positive
TR19 Negative Positive
Elite controllers
W-20 Negative Positive
W-350 Negative Positive
W-351 Negative Positive
W-352 Not determined Not determined
TR15 Positive Positive
TR16 Negative Positive
Progressive disease
W-4 Negative Positive
W-17 Negative Positive
Table 3
Extent of CpG methylation in the 5′-region and 3′-region of HIV-1 proviruses. CpG
methylation was determined by the bisulﬁte sequencing method (Frommer et al.,
1992; Clark et al., 1994). The percentage of unmethylated CpG’s in genome regions
as indicated was recorded. ND—not determined.
Subject Date 24–922 bp
Unmethylated CpGs (%)
8371–9494 bp
Unmethylated CpGs (%)
W-1 06/1995 ND 100
05/1996 35 28
04/2003 ND 68
04/2006 ND 100
W-21 01/1997 ND 100
03/2001 ND 100
06/2006 ND 100
W-360 07/1996 100 100
TR19 03/1997 100 98.9
W-20 09/1997 ND 100
04/2006 ND 100
07/2006 ND 100
W-350 05/2002 100 100
10/2002 ND 98.8
W-351 03/2002 ND 100
W-352 03/2002 ND 100
01/2006 ND 100
07/2006 ND 100
TR15 03/2007 ND 100
TR16 12/2006 ND 100
W-4 08/1999 98.8 98.6
W-17 06/1999 ND 99
901148 02/2009 97.5 98.5
901196 02/2009 99.6 100
901251 02/2009 98.9 100
901271 02/2009 99.8 99.7
901330 02/2009 100 100
901448 02/2009 98.4 100
901496 02/2009 97.5 100
901498 02/2009 100 98.5
135945a 05/2013 100 ND
138399a 07/2013 100 ND
139847a 08/2013 100 ND
ND¼not determined.
a Only CpG pairs 2 to 11 were analyzed.
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asymptomatic untreated HIV-1 infection (Table 1). Yet the proviral
genomes obtained from her PBMC’s during this period were
unmethylated at two time points (1995 and 2006) and partly
methylated at two other times (1996 and 2003) (Fig. 2A–D;
Tables 1 and 3). For unknown reasons, proviral DNA methylation
can ﬂuctuate in some HIV-1 infected individuals without apparent
effects on viral replication. Investigation of the DNA samples exhibit-
ing methylated HIV-1 proviruses (Fig. 2B and C) revealed no evidence
for appreciable 5-hmC levels. At three time points during HIV-1
infection (Table 2), our analyses of DNA from subject W-1 detected
exclusively integrated proviral HIV-1 genomes, but no 2-LTR circles.
The temporal ﬂuctuation in proviral DNA methylation at a given
time in the same individual W-1 might be a highly signiﬁcant
observation and may in part explain different ﬁndings by different
laboratories. Multifactorial parameters such as intercurrent infec-
tions, drug use, hormonal inﬂuences, or ﬂuctuating viral reservoirs
and cell populations could have played a role. Moreover, HIV-1
proviruses may have been integrated at different sites in the cellular
genomes at various times after infection, leading to variable
patterns of CpG methylation. In a different biological system, we
have found earlier that the de novo methylation patterns of
integrated plasmid constructs in mouse ES cells appeared to depend
on the site of plasmid DNA insertion (Hertz et al., 1999). The
documented resistance to de novo methylation might also be
explained by the ﬁnding that DNA methyltransferases cannot
modify CpG’s in certain sequence or conformational environments
(Jurkowska et al., 2011). HIV-1 has developed multiple strategies to
escape host defense mechanisms, among them that of avoiding de
novo methylation upon integration. It will be of considerable
interest to further evaluate this presumptive escape mechanism.
Conclusions
Several laboratories have reported that HIV-1 proviral CpG
methylation plays a role in HIV-1 infected cells in culture (Bednarik
et al., 1987, 1990; Blazkova et al., 2009; Chavez et al., 2011; Fang et al.,
2001; Gutekunst et al., 1993; Ishida et al., 2006; Jeeninga et al., 2008;
Kauder et al., 2009; Mok and Lever, 2007; Pion et al., 2003; Schulze-
Forster et al., 1990; Tanaka et al., 2003; Terme et al., 2009). Our data
examining multiple sites across the HIV-1 proviral genome in PBMC-
derived DNA from individuals with a wide range of HIV-1 disease, as
well as the results of recently published studies (Blazkova et al., 2009,
2012; Murphy et al., 2012; Palacios et al., 2012), are at variance with
this view. The unmethylated state of all CpG’s in major segments of
the HIV-1 proviral genome in 22 of 23 subjects suggests that proviral
DNA methylation is unlikely to serve as the major regulator of HIV-1
gene silencing in PBMC’s. The paucity of methylation in vivo may
facilitate HIV-1 expression by avoiding transcriptional silencing. The
apparent difference between infected individuals and cells in culture
can be explained by surmising that the speciﬁc CpG methylation
proﬁles in HIV-1 genomes arose under the pressure of “natural”
selection in HIV-1-infected individuals. In contrast, under cell culture
conditions, HIV-1 proviral genomes are not subject to the selective
pressure exerted by defense systems operative in the human host.
Studies in the future will aim to examine the genetic and epigenetic
characteristics of HIV-1 proviral genomes in humans and in animal
models, focusing on particular cell types including resting CD4þ T
cells, dendritic cells, and viral reservoirs.
Methods
Detection of 5-mC by bisulﬁte sequencing of DNA
In a cohort of HIV-1 infected individuals at different stages of
infection, we studied the methylation status of HIV-1 proviruses in
PBMC’s by bisulﬁte sequencing. This technique permits the unequi-
vocal differentiation between cytidine (C) and 5-methylde-
oxycytidine (5-mC) residues in a DNA sequence (Frommer et al.,
1992; Clark et al., 1994). Technical details of the method were
described previously (Hochstein et al., 2007; Naumann et al.,
Fig. 2. (A)–(D) Longitudinal study of DNA methylation proﬁles in the HIV-1 progenomes in PBMC’s from long term non-progressing individual W-1. Blood samples were
drawn at times as indicated on top of each graph. Individual W-1 was infected with HIV-1 probably in the late 1980s. All other symbols are as listed in the legend to Fig. 1.
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2009). In Table 4, all primers and the experiments in which they
were used were listed.
Detection of 5-hmC
For the detection of 5-hmC in the few DNA samples which had
been identiﬁed to contain 5-mC, the MethylFlash Hydroxymethy-
lated DNA Quantiﬁcation Kit (Epigentek) was used. The percentage
of hydroxymethylated DNA was estimated in a reaction of the
matrix-bound DNA with capture and detection antibodies and by
quantifying the reaction colorimetrically.
Detection of small circular DNA
DNA from PBMC´s was extracted with the MagnaPure DNA
large volume kit (Roche Diagnostics, Mannheim, Germany). In a
reconstruction experiment, we added DNA of the 5.65 kbp bacter-
ial plasmid pEGFP-FMR1 or of the 14.8 kbp plasmid pNL4-3-dE-
EGFP directly to the PBMC´s immediately prior to DNA extraction
and puriﬁcation by methods as recommended by the manufac-
turer. In the ﬁnal DNA preparation, the two different plasmid
DNAs could be readily detected by PCR using primers inside the
plasmid DNA sequence. The results of this reconstruction experi-
ment demonstrated that HIV-1 2-LTR circles of about 9.7 kbp
length would have been co-extracted with the proviral HIV-1
Table 4
All primers used in the experiments described here are listed and assigned to individual PCR experiments. Primers were those used by
HYPERLINK \l "MEP_L_tbl4fna" \o "aBlazkova et al. (2009). "aBlazkova et al. (2009), b (2012); c primers used by Friedrich et al. (2010).
Primer bisulﬁte sequencing Sequence 5′-3
MBa TGGTAGAATTATATATTAGGGTTAGGGATT
MHa CACCCATCTCTCTCCTTCTAACCTC
MCa AGAGAAGGTAGAAGAAGTTAATGAAGGAGA
MFa AAATCTAAAAAATCTCTAATTACCAAAATC
F1b TAGATATTTATTGATTTTTGGATGGTG
R1ab CACCCATCTCTCTCCTTCTAACCTC
F2b AGTGTTAGTGTGGAGGTTTGATA
R1bb AAAAAACTCCTCTAATTTYHCTTTC
HIV1 P1 f TTTTTTTGGTTAGATTAGATTTGAGTTT
HIV1 P2 r ATAATAATCTAAATTCTTCTAATCCTATCT
HIV1 P3 f n TTGTTTTGAGTGTTTTAAGTAGTGTGTGTT
HIV1 P4 r n ATCCCAATATTTATCTACAACCTTCTAATA
HIV P1n f TTTGGTTAGATTAGATTTGAGTTTG
HIV P3n r AATCTAAATTCTTCTAATCCTATCT
HIV P2n f n TTTGAGTGTTTTAAGTAGTGTGTGTT
HIV P4n r n TCCCAATATTTATCTACAACCTTCT
HIV1 P5 TTTAAGAATAGTTTTTGTTGTATTTTTTAT
HIV1 P6a r ACATTAAACAAACTAACAACACTATTCTTT
HIV1 P7 f n AGTGAATAGAGTTAGGTAGGGATATTTATT
HIV1 P8a r n AATTCCTAACTCCAATACTATAAAAAATTC
HIV1 P5a f AATATTGGTGGAATTTTTTATAGTATT
HIV1 P6 r ACACAAACAACATTAATAACTACTATATTA
HIV1 P7a f n AGTTAGGAATTAAAGAATAGTGTTGTTAGT
HIV1 P8 r n CTACTTATAATTACTCCATATTTTTCCAAA
HIV1 P5.2a f TAGTTTTTGTTGTATTTTTTATAGTGAA
HIV1 P6.2a r TTCTTTAATTCCTAACTCCAATACT
HIV1 P5i f n GAGTTAGGTAGGGATATTTATTATT
HIV1 P6i r n TTACAATCAAAAATAAATCTCTCAA
HIV1 P9 f AGAAGAGGTTAATAAAGGAGAGAATATTAG
HIV1 P10 r CAAATCTAATCTAACCAAAAAAACCCAATA
HIV1 P11 f n TTTGTTATATTTTGTGAGTTTGTATGGGAT
HIV1 P12 r n CAAACAAAAAACAACTACTTATATACAAAA
HIV-1 Integration
Alu1 forward fb GCCTCCCAAAGTGCTGGGATTACAG
HIV-1 gag reverse r b GCTCTCGCACCCATCTCTCTCC
LTR forward f n b GCCTCAATAAAGCTTGCCTTGA
LTR reverse r n b TCCACACTGACTAAAAGGGTCTGA
2-LTR circles
MH535 fb AACTAGGGAACCCACTGCTTAAG
MH536 rb TCCACAGATCAAGGATATCTTGTC
Detection of small circular DNA pEGFP-FMR1
Kan.pEGFP 5′ f ATGATTGAACAAGATGGATT
Kan.pEGFP 3′ r TCAGAAGAACTCGTCAACAA
pNL4-3-dE-EGFP
HXB2o P1 f TGGAAGGGCTAATTCACTCC
HXB2o P2 r CACACACTACTTGAAGCACTCAAG
HXB2o P3 f n AAGATATCCTTGATCTGTGG
HXB2o P4 r n CTTAAGCAGTGGGTTC
f¼forward, r¼reverse, n¼nested.
a Blazkova et al. (2009).
b Blazkova et al. (2012).
c Friedrich et al. (2010).
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DNA and would have been readily detectable by PCR if at all
present.
Methods of statistical analyses
The longitudinal data on CD4þ counts were analyzed by using
linear mixed models. Tests between groups were performed using
a Wilcoxon Rank Sum test, a non-parametric test.
The data described in this report were previously presented at
the XIX International AIDS Conference in Washington, DC in July
2012 (Weber et al., 2012).
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